Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Jaktinib in Adult Patients With Moderate and Severe Atopic Dermatitis
NCT05526222Phase 3Completed
- Sponsor
- Zelgen
- Start
- Jul 2022
- Primary completion
- Aug 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of jaktinib in atopic dermatitis (AD) (3 arms), sponsored by Zelgen. Primary endpoint: Efficacy in the treatment of moderate and severe atopic dermatitis at 16 weeks. Started Jul 2022; status: completed.
02
Drugs
jaktinib
03
Conditions
atopic dermatitis (AD)
Beyond the preview
Go deeper on NCT05526222.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05526222.